Opportunity Information: Apply for PAR 14 240
Apply for PAR 14 240
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on May 30, 2014 and posted on May 30, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Independent school districts Public housing authorities/Indian housing authorities City or township governments Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01) (PAR-14-240) was a National Cancer Institute (NCI), National Institutes of Health (NIH) funding opportunity designed to improve how mouse cancer models are used to support translational oncology research. The core idea behind the FOA was that mouse models (including human-in-mouse tumor models) are widely used in hypothesis-driven cancer biology studies, but the field has ongoing issues around how reliably those models predict or inform human patient outcomes. This program focused less on discovering a new mechanism in a single lab and more on making the models themselves more trustworthy, better characterized, and more appropriate for specific translational questions that ultimately matter for patient benefit.
A defining feature of the opportunity was its emphasis on true multi-site collaboration. Applicants were expected to form multidisciplinary teams and submit a linked set of R01 applications, with each participating site having its own Program Director/Principal Investigator (PD/PI). The structure was meant to support questions that one lab alone could not realistically answer, especially when the work requires different kinds of expertise (for example, mouse genetics, tumor immunology, imaging, pathology, computational analysis, pharmacology, or clinical translation) and when the study design benefits from replication across independent sites. The FOA explicitly highlighted that the linked awards would include an organized mechanism for cross-site communication and coordination, recognizing that reproducibility and standardization often depend on consistent protocols, shared benchmarks, and continuous alignment among collaborators.
In terms of scientific scope, the FOA invited projects that would expand, improve, or transform the utility of mouse cancer and tumor models for translational research. Rather than simply using mice as tools in a conventional R01 mechanistic project, teams were encouraged to tackle the practical and methodological barriers that limit model applicability. Examples of the kinds of efforts the FOA sought included demonstrations of how to overcome known limitations of oncology mouse models and human-in-mouse systems; defining new and credible ways to use existing models or mouse genetics for translational challenges that have not been adequately explored; advancing and disseminating better standard practices for translational model use; testing rigorous approaches to validate, benchmark, and "credential" models for particular uses; and, importantly, challenging common but potentially flawed practices in how models are interpreted and applied to translational decisions. The program was essentially an invitation to move beyond tradition or convenience in model selection and instead build an evidence-based foundation for when a given model is informative, when it is misleading, and how it can be improved.
From an administrative and funding standpoint, this was a discretionary grant opportunity using the R01 mechanism. The opportunity did not require cost sharing or matching. The award ceiling was listed as $450,000 (as provided in the source data). It was posted on May 30, 2014, with an original and current closing date of May 7, 2017, and it was archived on June 7, 2017, meaning it is no longer open for applications. The program was associated with multiple cancer-related CFDA numbers spanning cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), and cancer biology (93.396), reflecting that strengthening translational models can impact the entire continuum of cancer research.
Eligibility was broad and included a wide range of U.S. and non-U.S. organizations. Eligible applicants included public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses and for-profits other than small businesses); federal, state, county, city/township, special district governments; independent school districts; public housing authorities/Indian housing authorities; and Native American tribal governments and organizations (including federally recognized tribes). The FOA also explicitly included various mission- or population-focused institution types, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions. Foreign organizations and foreign institutions were eligible, as were non-domestic components of U.S. organizations, and foreign components were allowed consistent with NIH policy. Practically, this meant applicants could assemble international collaborations when the needed expertise, model resources, or validation cohorts were best achieved across borders.
Overall, PAR-14-240 was aimed at raising the scientific and translational standard for mouse-based oncology research by funding coordinated, multi-site teams to systematically evaluate, improve, standardize, and validate mouse cancer models. The intent was to make the resulting preclinical work more reliable, more comparable across laboratories, and more likely to produce insights and evidence that can be responsibly used to inform clinical hypotheses, therapeutic strategies, and patient-centered decisions.
Frequently Asked Questions (FAQs)
What is PAR-14-240?
PAR-14-240, titled "Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)," was a National Cancer Institute (NCI), National Institutes of Health (NIH) funding opportunity focused on improving how mouse cancer models are used to support translational oncology research.
What was the main purpose of this funding opportunity?
The program aimed to make mouse cancer models more trustworthy, better characterized, and more appropriate for specific translational questions, with the broader goal of improving how reliably findings from mouse studies can inform human patient outcomes and patient benefit.
Which NIH institute sponsored this opportunity?
This opportunity was sponsored by the National Cancer Institute (NCI) within the National Institutes of Health (NIH).
What grant mechanism did PAR-14-240 use?
The program used the NIH R01 research project grant mechanism, specifically as a collaborative R01 structure with linked applications across multiple sites.
Is this funding opportunity still open?
No. The opportunity was archived on June 7, 2017, meaning it is no longer open for applications.
When was the opportunity posted and when did it close?
It was posted on May 30, 2014. The original and current closing date listed was May 7, 2017. It was later archived on June 7, 2017.
What was the award ceiling?
The award ceiling was listed as $450,000 (as provided in the source data).
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
What kinds of research were encouraged under this FOA?
The FOA invited projects designed to expand, improve, or transform the utility of mouse cancer and tumor models for translational research. The emphasis was on tackling practical and methodological barriers that limit model applicability rather than focusing only on discovering a new mechanism within a single lab.
What types of mouse models were included?
The opportunity addressed mouse cancer models broadly, including human-in-mouse tumor models.
How was collaboration structured under this FOA?
A defining feature was true multi-site collaboration. Applicants were expected to form multidisciplinary teams and submit a linked set of R01 applications, with each participating site having its own Program Director/Principal Investigator (PD/PI).
Why did the FOA require multi-site collaboration?
The structure was intended to support research questions that one lab could not realistically answer alone, especially when multiple types of expertise are required and when replication across independent sites strengthens reproducibility, standardization, and confidence in findings.
What kinds of expertise did the FOA anticipate within collaborative teams?
Examples explicitly highlighted included mouse genetics, tumor immunology, imaging, pathology, computational analysis, pharmacology, and clinical translation.
Did the FOA address reproducibility and standardization across labs?
Yes. The linked awards were expected to include an organized mechanism for cross-site communication and coordination, reflecting the idea that reproducibility and standardization depend on consistent protocols, shared benchmarks, and continuous alignment among collaborators.
What does it mean that the program focused on making models more "trustworthy"?
In this context, it meant improving characterization, validation, benchmarking, and evidence-based selection of models so that researchers can better understand when a model is informative, when it is misleading, and how it can be improved for translational use.
What were examples of the types of efforts the FOA sought to fund?
Examples included: overcoming known limitations of oncology mouse models and human-in-mouse systems; defining credible new ways to use existing models or mouse genetics for translational challenges; advancing and disseminating better standard practices for model use; testing rigorous approaches to validate, benchmark, and credential models for particular uses; and challenging common but potentially flawed practices in how models are interpreted and applied to translational decisions.
Was the FOA intended for conventional mechanistic R01 studies?
The emphasis was not on simply using mice as tools in a conventional hypothesis-driven mechanistic project. Instead, teams were encouraged to address barriers that limit translational applicability and to improve the evidence base for model selection and interpretation.
What does "credentialing" a model mean in this FOA's context?
As described, credentialing referred to using rigorous approaches to validate and benchmark mouse models for particular translational uses, helping establish when a model is fit-for-purpose and what its limitations are.
What parts of the cancer research continuum were associated with this program?
The program was associated with multiple cancer-related CFDA numbers spanning cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), and cancer biology (93.396), reflecting that better translational models can influence many areas of cancer research.
Who was eligible to apply?
Eligibility was broad and included many U.S. and non-U.S. organization types, including public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses and for-profits other than small businesses); and multiple types of government entities.
Were government organizations eligible?
Yes. Eligible applicants included federal, state, county, city/township, and special district governments, as well as independent school districts and public housing authorities/Indian housing authorities.
Were tribal governments and tribal organizations eligible?
Yes. Eligible applicants included Native American tribal governments and organizations, including federally recognized tribes.
Were specific institution types explicitly included (such as HBCUs and HSIs)?
Yes. The FOA explicitly included institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions.
Were foreign organizations eligible to apply?
Yes. Foreign organizations and foreign institutions were eligible, and non-domestic components of U.S. organizations were eligible as well. Foreign components were allowed consistent with NIH policy.
Could this FOA support international collaborations?
Yes. Because foreign organizations were eligible and foreign components were allowed consistent with NIH policy, the opportunity could support international collaborations when expertise or resources were best achieved across borders.
What made this FOA different from a single-lab approach?
The FOA emphasized coordinated, multi-site teams working together to systematically evaluate, improve, standardize, and validate mouse cancer models, rather than focusing primarily on single-lab discoveries or convenience-based model selection.
What was the intended impact of PAR-14-240?
The intent was to raise the scientific and translational standard for mouse-based oncology research so that preclinical work becomes more reliable, more comparable across laboratories, and more responsible to use in informing clinical hypotheses, therapeutic strategies, and patient-centered decisions.
Browse more opportunities from the same category: Education Health
Next opportunity: DoD Prostate Cancer Exploration Hypothesis Development Award
Previous opportunity: Undergraduate Research Education Program (UP) to Enhance Diversity in the Environmental Health Sciences (R25)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 240
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 240) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01) Apply for PAR 14 241 Funding Number: PAR 14 241 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Oncology Models Forum (U24) Apply for PAR 14 239 Funding Number: PAR 14 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Limited Competition Biospecimen Banks to Support NCI Clinical Trials Network (NCTN) (U24) Apply for RFA CA 14 501 Funding Number: RFA CA 14 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $11,750,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions Coordinating Center and Data Management Group (U01) Apply for RFA CA 14 011 Funding Number: RFA CA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions (U01) Apply for RFA CA 14 010 Funding Number: RFA CA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovation Corps (I Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp) Apply for PAR 14 261 Funding Number: PAR 14 261 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
| Outstanding Investigator Award (R35) Apply for PAR 14 267 Funding Number: PAR 14 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1) Apply for RFA DA 15 008 Funding Number: RFA DA 15 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Connectomes Related to Human Disease (U01) Apply for PAR 14 281 Funding Number: PAR 14 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 011 Funding Number: RFA DA 15 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21) Apply for RFA DA 15 012 Funding Number: RFA DA 15 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Innovative Research in Cancer Nanotechnology (IRCN) (U01) Apply for PAR 14 285 Funding Number: PAR 14 285 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs) (U54) Apply for RFA CA 14 013 Funding Number: RFA CA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College Attending Youth (U01) Apply for RFA DA 15 010 Funding Number: RFA DA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Arts Based Approaches in Palliative Care for Symptom Management (R01) Apply for PAR 14 294 Funding Number: PAR 14 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 14 012 Funding Number: RFA CA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Approaches to Synthetic Lethality for Mutant KRas Dependent Cancers (U01) Apply for PAR 14 314 Funding Number: PAR 14 314 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Obesity and Asthma Awareness and Self Management (R01) Apply for PA 14 316 Funding Number: PA 14 316 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition AIDS Malignancy Clinical Trials Consortium (UM1) Apply for RFA CA 14 502 Funding Number: RFA CA 14 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $21,400,000 |
| Developing Interventions for Health Enhancing Physical Activity (R21/R33) Apply for PAR 14 321 Funding Number: PAR 14 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 240", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.